Medicine
Fresenius and WuXi Biologics announce agreement to expand biosimilars pipeline
The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates
Agentic commercial: AI redefines field, digital and content for precision engagement
Continuous engagement depends on a steady stream of timely, compliant content
AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences
The new site will expand research capabilities across immunology, neuroscience and oncology
The invisible influencer: the new information layer between doctors and scientific evidence
When priority scientific questions are being answered, how visible, accurate and useful is our evidence?
How pharma companies can use AI to scale personalized engagement without increasing complexity
AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing...
Creating the conditions for product launch success in a time of volatility
Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.
Navigating uncertainty in life sciences
The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments....
Inizio appoints Oisín Ó Gógáin as Chief People Officer
Inizio has appointed Oisín Ó Gógáin as Chief People Officer.
Karyopharm announces planned merger with Ayrmid amid Chapter 11 bankruptcy filing
The merger is not final and other companies will be able to bid for Karyopharm’s assets
The future of science communication is already on social
We need to make scientific information easier to find and support more evidence-based voices online
Veradermics announces phase 3 results for oral minoxidil for hair loss
If approved, it would be the only FDA-approved, oral, non-hormonal treatment for pattern hair loss in both male and female patients
Using the power of social media to break down obstacles preventing improved patient engagement
Connecting with patients and HCPs through social media channels needs care and consistency